Valerian effect on anxiety in postmenopausal women

Document Type : Original Article


1 Instructor, Department of Midwifery, School of Nursing & Midwifery, Islamic Azad University of Karaj, Karaj, Iran.

2 M.Sc. of Midwifery, School of Nursing & Midwifery, Tehran University of Medical Sciences, Tehtan, Iran.

3 Instructor, Department of Midwifery, School of Nursing & Midwifery, Tehran University of Medical Sciences, Tehtan, Iran.

4 Associate professor, Department of Biostatistics, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.


Objective: Menopausal is one of the crisis’s of women life and the signs women experience in this period is one of important care challenges and one of its most important consequences could be known as the concealed anxiety came out the menopausal. So the present study is aimed to evaluate the effect of valerian on the anxiety of menopause women.
Methods: This study is the kind of observational and clinical random traits studies. Sample cases of this study divided into two 72 individual groups of treatment and control randomly and a cross over design was done between two groups in the second phase of study. In the each period of experiment the treatment group received 530 mg valerian contained capsules two times per day and the control group received placebo capsules with the same apparent features. To measure the females’ anxiety, Espiell Berger concealed anxiety questionnaire was used and the paired sample mean compare test and repeated measure tests were used to analyze data in the statistical software SPSS.
Results: Results showed that using valerian has no significant effect on decreasing anxiety but its effect in the second test level and after receiving placebo was found significant that shows the effective role of cure period time on the efficiency of this drug.
Conclusion: It seems that the cure period has elementary role in valerian effectiveness on the decrease of postmenopausal women’s anxiety. ‎




    1. Muttukrishna S, Child T, Lockwood GM, Groome NP, Barlow DH, Ledger WL. Serum concentrations of dimeric inhibins, activin A, gonadotrophins and ovarian steroids during the menstrual cycle in older women. Hum Reprod 2000; 15(3):549–56.
    2. Melby MK. Chilliness: a vasomotor symptom in Japan. Menopause 2007; 14(4):752–9.
    3. Sievert LL. Menopause: a biocultural perspective. New Brunswick, NJ: Rutgers University Press; 2006.
    4. Ahmad S, Perviez MA, Thompson AK, Ullah H. Effects of storage of bananas in controlled atmosphere before ethylene treatments on its ripening and quality. J Agric Res 2007; 44(3):219–29.
    5. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet and Gynecol 2010; 190(4 Suppl):S5-22.
    6. Pines A, Stmurdee DW, Birkhäuser MH, De Villiers T, Naftolin F, Gompel A, et al. HRT in the early menopause: scientific evidence and common perceptions. Climacteric 2008; 11(4):267-72.
    7. Levasseur M, Tribble DS, Desrosiers J. Meaning of quality of life for older adults: importance of human functioning component. Arch Gerontol Geriatr 2009; 40(2):e91-100.
    8. Kuhner C, Burger C. Determinants of subjective quality of life in depressed patient: the role of self-esteem, response styles, and social support. J Affect Disord 2005; 86(2-3):205-13.
    9. Abasi E, Tafazzoli M, Esmaily H, Hasanabadi H. The effect of maternal-fetal attachment education on maternal mental health. Turk J Med Sci 2013; 43: 815-20.
    10. Kassim SH, Rajasagi NK, Zhao X, Chervenak R, Jennings SR. In vivo ablation of CD11c-positive dendritic cells increases susceptibility to herpes simplex virus type 1 infection and diminishes NK and T-cell responses. J Virol 2006; 80(8):3985–93.
    11. Kather A, Raftery MJ, Devi-Rao G, Lippmann J, Giese T, Sandri-Goldin RM, et al. Herpes simplex virus type 1 (HSV-1)-induced apoptosis in human dendritic cells as a result of downregulation of cellular FLICE-inhibitory protein and reduced expression of HSV-1 antiapoptotic latency-associated transcript sequences. J Virol 2010; 84(2):1034–46.
    12. Jones NL, Judd HL. Menopuase. In: Dechrney AH, Nathan L, editors. Current obstetrics & gynecology. 9th ed. North American: McGraw Hill Company; 2003. P. 1018-41.
    13. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Philadelphia: Lippincott Williams & Wilkins; 2002. P. 1443-4.
    14. Bauld R, Brown RF. Stress, psychological distress, psychosocial factors, menopause symptoms and physical health in women. Maturitas 2009; 62(2):160-5.
    15. Baksu B, Baksu A, Göker N, Citak S. Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial. Maturitas 2009; 62(2):140-5.
    16. McIntyre RS, Soczynska JK, Bottas A, Bordbar K, Konarski JZ, Kennedy SH. Anxiety disorders and bipolar disorder: a review. Bipolar Disord 2006; 8(6):665–76.
    17. Behboodi Moghadam Z, Rezaei E, Shirood Gholami R, Kheirkhah M, Haghan H. The effect of Valerian root extract on the severity of pre menstrual syndrome symptoms. J Tradit Complement Med 2016; 6(3):309–15.
    18. Najafzadeh M, Amini K, Faghihzadeh S, Monsef EH. Effect of valerian on anxiety of nurses working in the ICUs: a randomized controlled trial. Prev Care Nurs Midwifery J 2016; 5(2):1-12. (Persian).